NEXT Financial Group Inc Sells 2,600 Shares of Supernus Pharmaceuticals Inc (SUPN)

NEXT Financial Group Inc trimmed its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 31.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,720 shares of the specialty pharmaceutical company’s stock after selling 2,600 shares during the period. NEXT Financial Group Inc’s holdings in Supernus Pharmaceuticals were worth $228,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in SUPN. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Supernus Pharmaceuticals by 278.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its holdings in shares of Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after acquiring an additional 517 shares in the last quarter. Finally, Flinton Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 88.9% during the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after acquiring an additional 2,240 shares in the last quarter. Institutional investors and hedge funds own 98.22% of the company’s stock.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $46.50 on Thursday. The company has a market cap of $2,191.46, a price-to-earnings ratio of 43.87 and a beta of 1.18. Supernus Pharmaceuticals Inc has a 1 year low of $23.10 and a 1 year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. Supernus Pharmaceuticals’s revenue was up 41.5% compared to the same quarter last year. equities research analysts anticipate that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

Several analysts recently issued reports on SUPN shares. Cowen reiterated a “buy” rating and set a $50.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Jefferies Group reiterated a “buy” rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. FBR & Co started coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price objective for the company. Cantor Fitzgerald reiterated a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Finally, Stifel Nicolaus upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $49.90.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 5,750 shares of the stock in a transaction on Friday, January 12th. The shares were sold at an average price of $45.03, for a total transaction of $258,922.50. Following the transaction, the vice president now directly owns 15,094 shares of the company’s stock, valued at $679,682.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Insiders have sold 145,750 shares of company stock worth $6,173,173 over the last three months. Company insiders own 6.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3143989/next-financial-group-inc-sells-2600-shares-of-supernus-pharmaceuticals-inc-supn.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.